Bridge Neurotech

Bridge Neurotech (Redwood City, founded 2026) is building a fully non-invasive BCI: functional ultrasound imaging (fUSI) of brain activity through the skull, decoded with AI models. The bet is that ultrasound avoids the resolution, reliability and power weaknesses of earlier non-invasive modalities while needing no surgery or implant.

Status (October 2026)

Per the founder’s letter and Butterfly Network’s press release:

• emerged from stealth on Oct 6, 2026

• raised $13.5 million led by reMind Capital and General Catalyst, joined by Sunflower Capital and Scott Sandell

• research and development agreement with Butterfly Network (NYSE: BFLY) through Butterfly Embedded: Bridge licenses Butterfly’s Ultrasound-on-Chip technology; the multi-year agreement includes payments to Butterfly for technology access and development milestones plus commitments to purchase Butterfly hardware

• first human research study is enrolling in Redwood City: adults who have had a cranioplasty with a PEEK or Longeviti implant, and healthy adults 18 and older

• Founder’s letter (Will Biederman, Oct 2026): ⁰¹

• Butterfly Network press release (Oct 6, 2026): ⁰²

Founder

Will Biederman, PhD. In his own account in the letter: as a PhD student at Berkeley he developed the neural interface chip that Neuralink used for its first implants; he then spent almost a decade at Verily and Google, and co-founded Forest Neurotech, where he led development of a miniaturized functional ultrasound imaging device used to image the human brain. Forest Neurotech has since been renamed Arbor Neuroscience (the organization’s own site, forestneurotech.org: “Arbor Neuroscience is the new name for Forest Neurotech”, verified 2026-10-23).

What to watch

1. Through-skull imaging quality: the skull scatters and absorbs sound differently per person, which the company names as its core technical challenge.
2. Whether the first study produces published decoding results in humans.